BioCardia, Inc. (BCDA): Nasdaq/NYSE listing notice — BioCardia fails to regain Nasdaq compliance; delisting hearings requested

BioCardia, Inc.

Nasdaq determined BioCardia failed to meet $35M MVLS requirement by March 4, 2024.
Also failed to meet minimum bid price of $1.00 by March 11, 2024.
Company requested hearing by March 13, 2024, which stays suspension pending panel decision.
No assurance of continued listing; delisting could impair capital raising and stock liquidity.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BioCardia, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

September 13, 2023, the Company received a separate written notice (the “Minimum Bid-Price Notice”) from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Minimum Bid-Price Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company would have an initial period of 180 calendar days, or until March 11, 2024 (the “Minimum Bid Price Compliance Date”), to regain compliance with

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BioCardia, Inc. received a nasdaq hearing update notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: hearing update
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

March 12, 2024. Additionally, as previously disclosed on a Current Report on Form 8-K filed with the SEC on September 15, 2023, on September 13, 2023, the Company received a separate written notice (the “Minimum Bid-Price Notice”) from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Minimum Bid-Price Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company would have an

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BioCardia, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

on September 13, 2023, the Company received a separate written notice (the “Minimum Bid-Price Notice”) from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Minimum Bid-Price Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company would have an initial period of 180 calendar days, or until March 11, 2024 (the “Minimum Bid Price Compliance Date”), to regain compliance w

View on SEC.gov

94 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BioCardia, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-007467

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.